TSVT Live signals | Maximize Profits with Getagraph.com

BUY 157530 min ago

@ $5.61

Issued: 14 Feb 2024 @ 15:45

Return: -24.60%

Previous signal: Feb 14 - 13:38

Previous signal: Sell

Return: -2.09 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States...

Stats
Today's Volume	337 937
Average Volume	1.01M
Market Cap	217.44M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $-0.350 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.970
ATR14	$0.0170 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-03	Snow Jessica	Sell	15	Common Stock
2024-04-01	Snow Jessica	Buy	62 500	Stock Options (Right to buy)
2024-04-01	Snow Jessica	Buy	31 250	Common Stock
2024-04-01	Eatwell Victoria	Buy	42 500	Common Stock
2024-04-01	Eatwell Victoria	Buy	85 000	Stock Options (Right to buy)

INSIDER POWER
82.53
Last 92 transactions
Buy: 4 602 489 \| Sell: 363 012

Volume Correlation

Long: -0.15 (neutral)

Short: -0.32 (neutral)

Signal:(50.378) Neutral

2seventy bio, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

2seventy bio, Inc. Correlation - Currency/Commodity

0.32
( neutral )

0.27
( neutral )

0.00
( neutral )

0.34
( neutral )

-0.07
( neutral )

2seventy bio, Inc. Financials

Annual	2023
Revenue:	$100.39M
Gross Profit:	$73.18M (72.90 %)
EPS:	$-4.42

FY	2023
Revenue:	$100.39M
Gross Profit:	$73.18M (72.90 %)
EPS:	$-4.42

FY	2022
Revenue:	$91.50M
Gross Profit:	$65.28M (71.34 %)
EPS:	$-7.13

FY	2021
Revenue:	$54 522.00
Gross Profit:	$52 005.00 (95.38 %)
EPS:	$-0.0126

Financial Reports:

No articles found.

2seventy bio, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

2seventy bio, Inc.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.